Related Experiment Videos
Drug therapy for double-hit lymphoma
Vania Phuoc1, Jose Sandoval-Sus2, Julio C Chavez3
1Division Hematology/Oncology, University of South Florida, Tampa, FL, USA.
Drugs in Context
|December 18, 2019
Summary
Double-hit lymphoma (DHL) is an aggressive cancer requiring intensive chemotherapy. Novel therapies targeting MYC pathways, stem cell transplants, and CAR T-cell therapy offer new hope for these challenging B-cell lymphomas.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Double-hit lymphoma (DHL) is a rare, aggressive B-cell malignancy characterized by MYC and BCL2/BCL6 gene rearrangements.
- Patients often present with advanced-stage disease and extranodal involvement, frequently exhibiting resistance to standard treatments like R-CHOP.
Purpose of the Study:
- To review the current understanding of double-hit lymphoma (DHL) pathogenesis and treatment strategies.
- To explore emerging therapeutic targets and advanced treatment modalities for DHL.
Main Methods:
- Literature review of studies on double-hit lymphoma (DHL).
- Analysis of treatment outcomes with conventional and novel therapeutic approaches.
- Discussion of the role of hematopoietic stem cell transplantation (HCT) and CAR T-cell therapy.
Main Results:
- MYC rearrangements are key drivers in DHL, presenting significant therapeutic challenges.
- Standard chemotherapy regimens are often insufficient, necessitating aggressive approaches like DA-EPOCH-R or R-hyperCVAD.
- Hematopoietic stem cell transplantation (HCT) and CAR T-cell therapy show promise in refractory/relapsed settings.
Conclusions:
- Double-hit lymphoma (DHL) requires tailored, aggressive treatment strategies.
- Targeting MYC-associated pathways and utilizing novel agents (e.g., BCL2 inhibitors, BET inhibitors) are critical areas for future research.
- Allogeneic stem cell transplantation and CAR T-cell therapy represent important therapeutic options for eligible DHL patients.